Blue Origin receives $7M grant for facility upgrades
EL PASO, Texas (KTSM) – The Texas Space Commission has awarded a $7 million grant to Blue Origin for upgrades, Senator César J. Blanco announced on Wednesday, Feb. 12.
Blanco said the funding will be used for upgrades to its horizontal first-stage booster engine test facility.
The funding will also support the addition of subcooling capacity, allowing the use of more energy-dense propellants in the New Glenn program, Blanco added.
New Glenn, a reusable rocket designed for heavy payloads, is part of Blue Origin's long-term vision to expand human and industrial activity into space.
Blanco said these improvements will enhance the thrust capacity of each booster engine, further strengthening Texas' role in space innovation.
Blanco shared the following statement:
'Last session, I was proud to pass legislation to create the Texas Space Commission to grow the space industry in Texas, attract cutting-edge research, and support companies like Blue Origin that are investing in West Texas.
'This grant is another step in building up our region as a hub for aerospace innovation, creating new opportunities and good-paying jobs, while strengthening our role in the future of spaceflight.'
Summer Webb, director of Texas Government Relations, Blue Origin sent the following statement:
'We're grateful for our partners in the State of Texas and the Texas Space Commission for the Space Exploration and Aeronautics Research Fund grant. This cost-share agreement with Blue Origin will be used for research, development, and testing at our West Texas facility. Public-private partnerships like this benefit the growth of the space economy and drive innovation in Texas. We look forward to growing our partnerships in the Lone Star State, where our investment now exceeds one billion dollars — to sustain American leadership in space.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Army surveillance balloons spotted over Tucson raise privacy concerns from advocates
An Aerostar high-altitude balloon as seen from the ground in Tucson. Photo by Dugan Meyer The U.S. Army and a private company are flying high-altitude surveillance balloons over the Tucson area, raising concerns among privacy advocates. Multiple high-altitude balloons have been spotted over the Tucson and Sierra Vista area for more than a week, with one balloon in particular staying over the area longer than any of the others. That balloon, with the registration number N257TH, has made headlines in the past. The balloon is owned by South Dakota aerospace company Aerostar, and in 2023 was mistaken for a Chinese spy balloon. The balloon is actually part of Aerostar's 'Thunderhead' balloon system, which has been doing multiple tests with the military and other contractors across the nation and around the globe. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'It is a technology that should not and constitutionally cannot be applied to the American people,' Jay Stanley, a senior policy analyst at the American Civil Liberties Union, told the Arizona Mirror. 'Even testing for eventual overseas use in legitimate combat theaters raises a lot of questions about what kind of data is being collected.' Aerostar would not answer specific questions about what type of testing was being done. The company referred additional questions to the U.S. Department of Defense and the Army, neither of which responded to multiple requests for comment. Aerostar confirmed that the flights were not connected to U.S. Customs and Border Patrol or Department of Homeland Security programs, 'however high-altitude balloons would be ideal for that type of mission,' Aerostar Culture and Communications Director Anastasia Quanbeck said in an email to the Mirror. 'By leveraging directional wind patterns at high altitudes, Aerostar's Thunderhead Balloon Systems offer groundbreaking capabilities for navigation and persistence over areas of interest,' she said. 'Aerostar Thunderhead Balloon Systems are capable of supporting intelligence, surveillance, and reconnaissance missions, as well as extending communications across wide distances, environmental monitoring, earth observation, and scientific research.' Quanbeck said she was not able to discuss the work the company does with the DOD or the Army. The 'Thunderhead' balloons are similar to 'spy balloons' that have made international headlines in recent years. They fly between 60,000 to 100,000 feet, twice the height of a commercial airliner, and can carry much larger payloads than a conventional drone or other small high altitude spy-planes. After Chinese spy-balloons made incursions into United States airspace in 2023, it was reported that the Army would begin pursuing a similar program to launch in 2025. Aerostar had previously been used in testing exercises. In the past, Aerostar has used blimps as surveillance systems. They were originally used for surveillance in combat zones overseas, then in 2012 were used along the border and still are often spotted at the border today. However, the systems that have been seen floating over southern Arizona in recent weeks have key differences from the blimps: they sit higher in the sky, are much larger, can stay afloat for much longer and can carry larger payloads. As reported by The War Zone, the Army has been researching using high-altitude balloons to deploy drone swarms into enemy territory far above the reach of enemy defenses. But the balloons over southern Arizona raise questions about privacy. In 2021, the 4th U.S. Circuit Court of Appeals ruled that the Baltimore Police Department's use of an aerial surveillance program that recorded virtually all of the city for 12 hours a day for six months was unconstitutional. Stanley thinks that case is pertinent when talking about what may be going on in Arizona. 'I think, if anything, it becomes more sensitive when the military is doing it,' Stanley said. Wide-area persistent surveillance or wide-area airborne surveillance is a technique that got its start in early days of the Iraq war but later would find itself in the hands of police. The technology has evolved from being very heavy but is now light enough to fit onto blimps and balloons. Aerostar and the military have not elaborated on what systems are aboard the balloons over the Tucson area, but Stanley said that systems like the ones Aerostar is developing could be used to deploy persistent surveillance systems, ultimately surveilling entire communities for days on end. The Thunderhead system boasts the ability to stay afloat for up to 30 days, and Aerostar has tested it along with its Zephyr platform, a new type of unmanned aircraft that also flies at high altitudes and has been tested in Arizona. That aircraft can stay in the air for up to two months. The balloon also could be carrying a variety of equipment, such as radar, lidar, GPS or cameras, Stanley said. While much of this equipment could be installed on a traditional aircraft, the balloon can stay afloat over an area at a higher altitude for longer durations, allowing for more persistent surveillance of an area, something that Stanley said can be a problem for everyday Americans. 'Following someone around for long periods of time reveals things about their life,' Stanley said. 'How often they go to the bar, associations, who they are hanging out with — and that is too much power for the government or anyone else to have over individuals.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
Boston Globe
an hour ago
- Boston Globe
From no hope to a potential cure for a deadly blood cancer
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients -- a result never before seen in this disease. Advertisement These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. June has seen patients who lost 6 inches in height. Advertisement 'It's a horrible, horrible death,' June said. 'Right now advanced myeloma is a death sentence.' (June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Advertisement Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge -- helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study -- they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Advertisement Taking the Legend CAR-T was difficult -- she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache -- or an old one -- can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Sharpless said. And for those like the patients in the new study who are living at least five years -- so far -- without disease, the outcome 'really is eye-popping,' Sharpless said. Advertisement 'That's getting to a point where you wonder if it will ever come back,' he added. This article originally appeared in
Business Journals
2 hours ago
- Business Journals
Near, Skilled, and Experts in AI: Latin America's Tech Edge
Firms like Glofy are helping U.S. tech leaders build high-performing distributed teams with strategic alignment. As demand for top-tier developers soars, U.S. companies are re-evaluating their outsourcing playbooks. Attention is shifting from longtime hubs such as India and Eastern Europe toward Latin America, where time-zone alignment and cultural affinity complement deep technical talent. The region now boasts a fast-growing pool of specialists in AI, machine learning, and data science, fluent in North-American business norms and English. Industries tapping that talent range from healthcare, insurance, and government to venture-backed tech startups. Glofy fills roles in mainstream stacks: .NET, Python, React and, increasingly, in enterprise platforms like SAP and Microsoft Dynamics, matching the market's appetite for large-scale system expertise. 'Glofy gives us both the speed and domain depth a high-stakes sector demands,' says Nicholas, Director of Technology at a company pioneering AI-driven analytics for high-risk patients. 'Their developers arrive trained and industry-savvy, cutting our onboarding curve and letting us execute fast where it matters most.' How Glofy Keeps Quality High Beyond simple staff augmentation, Glofy runs a four-stage talent funnel: a calibrated code challenge, live pair-programming with a senior engineer, a soft-skills and English assessment, and a cultural-fit interview focused on North-American agile rituals. Fewer than 3% of applicants clear all stages. The result is a bench of bilingual specialists ready to slot into daily stand-ups, sprint reviews, and late-night incident calls without friction. Clients report ramp-up times trimmed by 40% and turnover rates well below regional averages metrics that translate into real velocity and cost certainty on complex roadmaps. 'Companies aren't just outsourcing tasks anymore, they're seeking integration, innovation, and velocity, all powered by AI and business insight,' notes Gonzalo Rosa, CEO of Glofy. With a vibrant tech ecosystem and surging AI focus, Latin America is no longer an alternative; it's the go-to region for scaling with vision and precision. Among the companies leading this shift, Glofy stands out as a quiet force driving growth with purpose.
